Therapeutic antibody development company Patrys (ASX:PAB) has announced new pre-clinical data for its lead asset, PAT-DX1, from a study conducted by Professor Terrence Johns of the Telethon Kids Cancer Centre. …
Partrys' candidate in combination improves survival in brain cancer model
August 11, 2022 Australian Biotech
Latest Video
New Stories
-
Vitex opens $250 million pharmaceutical manufacturing facility in Western Sydney
July 6, 2026 - - Latest News -
Early clinical imaging shows Syntara candidate reduces brain inflammation in people at high risk of Parkinson’s
July 6, 2026 - - Australian Biotech -
Widespread use of statins narrows heart-risk gap between overweight and normal-weight adults
July 6, 2026 - - Latest News -
A performative change that still leaves the door open for a response to 'MFN' risk
July 6, 2026 - - Latest News -
New law proposes limiting trade minister's power over PBS concessions
July 6, 2026 - - Latest News -
The 'Dispatched' Podcast - Season 5, Episode 22
July 3, 2026 - - Podcast -
Is that a subtle but meaningful shift conceding the potential need for a response to global realities?
July 3, 2026 -